The US Food and Drug Administration granted approval for a new subcutaneous formulation of Merck's Keytruda cancer therapy, aiming to prolong the commercial competitiveness of the world's leading oncology drug. This regulatory milestone comes amid efforts to deter biosimilar competition and enhance patient convenience. The approval was accompanied by positive European recommendations for similar subcutaneous immunotherapies, signaling a shift towards easier administration methods in cancer care.